Rakovina has been invited to present at the 6th biennial Canadian Cancer Research Conference which is being held virtually Nov. 8-11, 2021.

Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors..

Apabetalone is the only drug of its class with a well-established safety record in human clinical trials, with well over 4200 patient-years

The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics’ kt-2000 series...

"In February 2020, Apabetalone became the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation, for a...

Successful Completion and Promising Results of Investigator-led APPROACH-p Trial Sets the Stage for a Larger Multicenter Trial

Velada brand cannabis products both online and in store in the province of ON starting January 2022

The conference has attracted academics, scientists, and pharmaceutical industry representatives from across the globe.....

TGSC has also initiated a podcast marketing campaign with AdvertiseCast to continue expanding their e-commerce presence throughout NA..

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19...

Good Shroom, through its wholly owned subsidiary, Teonan, manufactures and sells functional beverages under its two brands, Teonan, a...

MUSH is expected to gain exposure to Ecotrend Ecologics Ltd.'s network of 2,500 retailers in Canada, which includes Whole Foods, Well.ca...

Rakovina is pleased to report steady progress in research activities as they establish Rakovina as a publicly listed company...

Agreement allows for Hepalink to purchase 10% secured convertible debentures in the aggregate principal amount of US$6 million...

The introductory order of 3,000 units allows to establish a relationship with Good Food and expect, will lead to additional orders...

Rakovina announced the formation of its Scientific Advisory Board. Made up of experts in biology, medicinal chemistry and pharmacology...

“Amazon’s Choice” designation is achieved by high star rating, competitive price, low return rate, consistent inventory, and high sales..

The company’s focus is the development of new cancer treatments and is researching and developing new precision medicines targeting critical

Micron Technologies has submitted its N95 Model 8800 face masks to NIOSH and is confident it will obtain NIOSH certification...

Dr. Cherrington is an accomplished life science executive with a record of success bringing drug candidates through to commercialization...

The company will focus on the development of novel DNA-damage repair (DDR) inhibitors for the treatment of cancer

Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart..

This collaborative research effort, employing state-of-the-art methods, has demonstrated apabetalone’s potential...

Following new published evidence of apabetalone's benefit in COVID-19 Resverlogix is announcing the initiation of human clinical trials..

Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model..

Liquid Avatar provides users, at no cost, digital tools to create, manage and control their biometric based, Self Sovereign Identity....

The Horizons Psychedelic Stock Index ETF index is expected to start trading on Tuesday, January 26 under the ticker PSYK on the NEO Exchange

The biosynthetic platform provides a potential simple and efficient method for rapidly producing natural

The Company’s clinical safety team has actively monitored ongoing interim data of patients and found there have been no safety concerns.....

The final terms will be agreed to by the parties after the completion of due diligence by Revive - Expected to close on or before Jan.31.21

Liquid Avatar Partners with Fintech Innovator XTM to enable Hospitality, Personal Care and other Sectors to Verify COVID19 Vaccine....

Liquid Avatar, Lumedic, Loop Insights, The Campus Agency and TripXpertz Form Consortium to Manage Verifiable Identity Credentials for...

Algernon has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study...

Algernon is pleased to announce that it has now enrolled 100 patients, which is two thirds of it enrollment target...

The Company has selected and finalized with five clinical sites in Florida, Texas and California for enrollment of patients in the Phase 3..

Algernon has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Aug. 14,...

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19...

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics Developed Prototypes of Orally Dissolvable Thin Film For Psilocybin

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Relevium Licenses Patented Science-Based Natural Formulation That Addresses Major Points of Viral Invasion, Replication and Toxicities

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Voyageur Signs LOI to Engage THINQ for Pharmaceutical Consulting, and Collaboration on Long Term Pharmaceutical Drug Development Calgary,...

Algernon Pharmaceuticals completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in...